Kopran Peer Comparison

NSE: KOPRAN | BSE: 524280

₹279.42

₹2.98 (1.08%)

As on 23-Sep-2026IST

Market cap

₹1,350 Cr

Revenue (TTM)

₹700 Cr

P/E Ratio

P/B Ratio

2.5

Div. Yield

1.1 %

Edit

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	1,350	37,857	27,713	26,763	28,045
Revenue (₹ Cr)	700	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	24.98	414.00	288.22	387.35	-371.81
Net Margin (%)	3.56	11.23	14.79	26.01	-3.93
RoE (%)	4.84	8.38	29.77	25.18	-3.85
Price to Earnings	54.02	92.56	96.15	69.30	--
Price-To-Book	2.52	7.52	20.65	15.51	3.50

Income Statement (₹ Cr)

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	700.20	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	702.44	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	638.97	2,792.00	1,485.56	919.25	8,195.15
EBITDA	61.23	772.00	450.24	542.56	1,010.13
Depreciation	18.99	226.00	50.83	37.68	857.51
EBIT	42.25	546.00	399.41	504.88	152.62
Interest	11.22	217.00	40.84	3.77	342.73
Other Income	2.24	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	33.27	463.00	371.35	528.56	-162.68
Provision for Tax	8.29	49.00	83.14	141.21	209.13
Profit after Tax	24.98	414.00	288.22	387.35	-371.81

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	530.28	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	31.90	1,712.00	202.03	42.40	5,044.14
Current Liabilities	346.18	1,622.00	835.87	230.82	4,758.28
Total Liabilities	908.36	8,578.00	2,326.71	1,983.96	17,723.32

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	371.29	5,343.00	519.60	1,026.85	10,211.52
Current Assets	523.18	2,606.00	1,681.81	881.27	7,191.66
Total Assets	908.36	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	152.69	2,125.00	259.37	26.49	5,495.48
Net Current Assets	177.00	984.00	845.94	650.46	2,433.38
Contingent Liabilities	18.95	768.26	19.09	17.25	95.72

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	66.75	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	-64.60	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	-20.94	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	-18.79	95.00	78.39	30.33	787.59

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	6.65	6.79	29.22	32.42	1.24
ROE (%)	4.84	8.38	29.77	25.18	-3.85
ROA (%)	2.85	4.94	24.77	21.93	-2.21
EBIT Margin (%)	6.03	15.32	20.63	34.54	1.66
Net Margin (%)	3.56	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	11.96	18.37	46.65	40.90	0.78
EBIT Growth (%)	-15.19	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	-28.43	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-28.47	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	2.36	13.47	144.31	26.03	0.33

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	53.98	95.00	94.68	69.29	-89.63
Price / Book Value	2.52	7.52	20.65	15.51	3.50
Dividend Yield (%)	1.07	0.00	0.09	0.08	0.00
EV/EBITDA	24.42	50.93	61.36	48.96	31.86
Market Cap (₹ Cr)	521.02	19,071.62	12,753.19	20,944.75	18,108.89

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.03	0.31	0.11	0.02	0.53
Short term debt to equity ratio	0.26	0.09	0.05	0.02	0.09
Current Ratio	1.51	1.61	2.01	3.82	1.51
Quick Ratio	1.04	1.06	1.14	2.82	0.87
Interest Coverage	3.97	3.13	10.09	141.16	0.53

	Kopran	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	37.51	16.50	26.28	24.80	23.44
Asset Turnover	0.80	0.43	1.66	0.83	0.55
Receivable days	127.91	58.75	40.13	88.98	78.20
Inventory Days	89.35	75.82	60.29	56.04	93.30
Payable days	122.98	186.21	232.47	99.95	226.14
Cash Conversion Cycle	94.28	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.